Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Edward van Vaesel says Europe generates nearly as much science and IP as the US, but lacks the capital markets, risk appetite and trial infrastructure to translate it. He notes European companies often run first trials in the US or Australia because patient access is faster and cheaper.

Related Insights

Europe, despite excellent science, lost its co-equal status in drug development to the U.S. due to restrictive pricing and lack of growth capital. These same challenges are now emerging in the U.S., threatening its innovation leadership as China accelerates its efforts.

Biotech developers are migrating toward transnational development models that execute early clinical de-risking in regions like China, Australia, or the UK. This approach accelerates progression while maintaining strict data quality standards required by Western regulators for commercial approval.

Edward van Vaesel says European biotechs often run first human trials in the US but also Australia, where patient access is faster, costs are lower and tax benefits exist. He ties this to Europe's fragmented 27-country trial bureaucracy. That makes Europe less attractive for early clinical development.

The UK produces world-class academic discovery but struggles to create scalable biotechs. The primary reason is a lack of venture capital with an appetite for the inherent risks of life sciences, forcing promising UK innovations to move to the US to secure funding.

The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.

Europe generates scientific output and IP comparable to the US but fails to translate it into successful companies at the same rate. Key challenges include a lack of deep capital markets, a lower cultural risk appetite, and a smaller talent pool, pushing many promising European biotechs to seek funding and IPOs in the US.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

To remain globally competitive against the US and China, European biotech should focus on its core strength: high-quality, innovative early-stage science. The speaker suggests that while Europe excels at invention, scaling companies still requires tapping into the US market, capital, and talent, positioning Europe as a premier origination hub.

Europe's strong science is often held back by a lack of serial entrepreneurs, difficulty in raising follow-on funding, and a localized competitive view. Curie.Bio’s model directly counters these issues by providing an experienced drug-making team, a clear funding path, and an embedded global market perspective.

While overall venture capital investment in European biotech is rising, a critical gap remains at the earliest stage of company formation. According to the speaker, founders still find it very difficult to secure the initial "first capital" needed to get started, even as later-stage funding has grown tremendously in the region.